Bank of America Securities analyst Sachin Jain maintained a Buy rating on Sanofi today and set a price target of €115.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Sachin Jain has given his Buy rating due to a combination of factors that highlight Sanofi’s promising pipeline and strategic positioning. The recent data from Sanofi’s Brivekimig trials show promising efficacy, particularly in the high efficacy segment, with ongoing trials in Crohn’s and UC indicating a broad potential for this asset. Furthermore, the feedback from key opinion leaders on Amlitelimab is strong, with positive surprises in the data and potential for commercial success due to its convenience and persistence.
Jain also notes the potential of Tolebrutinib in the SPMS market, with a significant addressable market and anticipated strong sales. Despite some pipeline setbacks, Sanofi’s valuation appears attractive, with a low price-to-earnings ratio undervaluing its growth prospects. The company’s strategic R&D spending and anticipated margin expansion by FY26 further support the Buy rating, as these factors suggest a positive outlook for Sanofi’s future performance.
In another report released today, Bernstein also maintained a Buy rating on the stock with a €119.00 price target.